Our team

 

Karolinska Development’s team has extensive experience of managing life science investments in a listed environment. Our employees’ day-to-day work involves ensuring that the portfolio companies have optimum value generation strategies, have sufficient resources to implement these strategies, and have world-leading expertise in business development and the scientific areas in which they operate.

Viktor Drvota

Chief Executive Officer

Viktor Drvota
Chief Executive Officer

Appointed as CEO on June 1, 2017 succeeding Jim Van heusden, and previously CIO since 2016.

Born 1965. M.D, Ph.D. Associate Prof. In Cardiology.

Viktor Drvota has over 20 years of Venture Capital experience with several investements, significant fundraisings, IPOs and exits. He was responsible for Life science at SEB Venture Capital 2002-2016. During his appointment at SEB VC he also served as a Board member in several biotech and Medtech companies such as Arexis AB, SBL Vaccin AB, Nuevolution AS, Index Pharma AB, Scibase AB, Airsonett AB among others. Before joining SEB in, Dr Drvota worked as Senior Consultant and Associate Professor in Cardiology at the Karolinska Institutet/hospital, Stockholm. Dr Drvota has experience from preclinical as well as clinical research in drug development and medical devices. Dr Drvota has 29 published research articles.

Holdings in Karolinska Development: 209,996 shares.

Johan Dighed

Chief Legal Officer and Deputy CEO

Johan Dighed
Chief Legal Officer and Deputy CEO

Appointed Chief Legal Officer 2020 and Deputy CEO 2021

Born 1973. Master of Laws.

Johan Dighed has over 20 years’ experience in financial and business law including positions as Head of Legal with the German bank SEB AG and legal counsel with SEB AB. Prior to joining the financial sector he worked with the international law firm Baker & McKenzie and in the Swedish Judiciary. 

Holdings in Karolinska development: 400,192 shares.

 

Hans Christopher ”HC” Toll

Chief Financial Officer

Hans Christopher ”HC” Toll
Chief Financial Officer

Appointed 2022.

Born 1968. MSc in Business and Economics.

HC Toll has more than 25 years of experience as business controller and CFO, in different industries, both in Sweden and internationally. HC has i.a. been CFO in AIK Fotboll AB and QuiaPEG AB. HC is since 2021 part time CFO in the KD portfolio company Umecrine Cognition AB.
In addition to life science, HC has experience in a range of industries, such as heavy manufacturing, retail, gaming, etc.

Holdings in Karolinska development: 35,000 shares.

Per Aniansson

Investment Director

Per Aniansson
Investment Director

Appointed 2021.

Born 1966. MSc Engineering Physics and MBA.

Per Aniansson has more than 20 years of VC experience. Per has also been CEO of two medtech companies and CFO in another VC backed start-up. He has responsible in several significant fundraisings, IPOs and exits. Between 2011-2019, Per was an Investment Director at Fouriertransform with a focus on medtech. During his appointment at Fouriertransform he also served as a Board member in OssDsign AB, Scibase AB, Renewcell AB, Powercell AB, SmartEye AB and AAC Clydespace AB. Prior to this Per has set-up and been the CEO at Icon Medialab Capital and MD Nordics for Siemens Mobile Acceleration, two corporate VCs. He was also an investment director at Innovationskapital, Investment responsible within Life Science at Industrivärden and a management consultant at Arthur D Little and Accenture.

Current Board assignments: AAC ClydeSpace and Cure Cancer Foundation.

Holdings in Karolinska Development: 160,006 shares.

John Öhd

Chief Scientific Officer/Venture Partner

John Öhd
Chief Scientific Officer/Venture Partner

Appointed 2020

Born 1971, M.D., Ph.D. John has broad knowledge and experience of drug development in several therapeutic areas, including CNS, cancer and blood disorders. He has held leadership roles within the research organizations of AstraZeneca, Shire Pharmaceuticals and Medivir. Before joining Karolinska Development he was the Chief Medical Officer of Modus Therapeutics. Prior to his drug development roles, John held various research and clinical positions at Lund University and Karolinska Institutet/University Hospital.

No holdings in Karolinska Development.

Elisabet Gimbringer

Financial Manager

Elisabet Gimbringer
Financial Manager

Employed since November 2015. Born 1965. Economics and Business education from Stockholm University. Elisabet has worked as an approved public accountant for 10 years, and as a financial manager, business controller and financial controller for a number of different companies and fields for the last 20 years.

Holdings in Karolinska Development: 30,000 shares.

Eva Montgomerie

Head of Accounting

Eva Montgomerie
Head of Accounting

Employed since October 2013, employed within the group since 2007.

Born 1958. MSc in Business and Economics.

Eva Montgomerie has worked within the bank and finance sector for 12 years, 10 years within the food and clothing sector and 10 years within life science.

Other appointments: Finance manager in Dilafor AB and Pharmanest AB.

Holdings in Karolinska Development: 23,865 shares.

Yan Cheng

President Asia

Yan Cheng
President Asia

Appointed 2020. 
 
Born 1985. BSc in Business. 
 
Yan Cheng has many years of experiences of Venture Capital in European life science companies and has been adviser to such companies on business development, especially on the Technology Transfer and Merges & Acquisitions activities between Asia and Europe. Yan Cheng also has experiences of fundraising from Fortune 500 companies, financial institutions, and family offices.

Holdings in Karolinska Development: 25,004 shares.

Linda Spahiu Elvesjö

Investment Manager

Linda Spahiu Elvesjö
Investment Manager

Born 1985. M.Sc. in Biotechnology, Ph.D.

Linda Spahiu has 13 years’ experience from the Life Science industry, ranging from academic and laboratory work to go to market strategies and commercial due diligences. Before joining Karolinska Development she was CEO of VOC Diagnostics, a Swedish startup in cancer diagnostics. Linda also holds experience from management consulting at Boston Consulting Group, working with projects exclusively within MedTech and Life Science.

Holdings in Karolinska Development: 10,003 shares.

Mikaela Sörman

Investment Manager

Mikaela Sörman
Investment Manager

Born 1990. M.Sc. in Public Health & Health Inequalities

Mikaela Sörman has 9 years experience from the health care industry. Before joining Karolinska Development she worked at Boston Consulting Group, a management consultancy firm, where she focused exclusively on MedTech and Life Science projects. Mikaela also holds experience from project management after working several years in a health care social start-up, Stiftelsen Choice.

Holdings in Karolinska Development: 10,003 shares.